Details checkedStrong evidenceCheckedtrial

AK-antiVEGF by Eli Lilly and Akouos

Also known as: AK-antiVEGF, AAVAnc80-antiVEGF, AAVAnc80-antiVEGF via Akouos Delivery Device

Eli Lilly and Company

Primary source

Company

Eli Lilly and Company

Program Type

Therapeutic

Modality

Gene Therapy

Stage

Phase 1/2

Status

Active

Target Gene

—

Route / Mode

Intracochlear administration via Akouos delivery device

Confidence

90%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-06-09

Geography

United States

Population

adult, unilateral, vestibular-schwannoma, hearing-adjacent

Trial IDs

Mechanism

AAVAnc80 vector-based therapeutic protein expression program designed to deliver anti-VEGF expression locally for unilateral vestibular schwannoma, with potential to preserve or improve hearing by modulating vestibular schwannoma biology.

Indications

Vestibular Schwannoma Hearing Loss

Notes

Verified active Akouos/Lilly clinical program. It is not a broad hearing-loss restoration program; it is a vestibular schwannoma program with hearing-preservation relevance through the vestibulocochlear nerve and local anti-VEGF expression.

Evidence & Sources

2 structured sources

company

Supports: canonicalName, aliases, company, allCompanies, modality, mechanism, indications, stage...

IDs: AK-antiVEGF, AAVAnc80-antiVEGF, NCT06517888

Open

clinicaltrials

Supports: trialIds, stage, status, populationTags, geography

IDs: NCT06517888

Open

Key Events

2024-10-16